J. Lyons

发表

Is a Potent and Oral Inhibitor of AKT and p 70 S 6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth

P. Workman, M. Walton, M. Garrett, 2010 .

AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth

P. Workman, M. Walton, M. Garrett, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics AT 7519 , a Cyclin-Dependent Kinase Inhibitor , Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

W. Qi, V. Lock, J. Lyons, 2010 .

AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient Samples

Wenqing Qi, W. Qi, V. Lock, 2010, Molecular Cancer Therapeutics.

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009, Molecular Cancer Therapeutics.

Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines

J. Lyons, N. Thompson, M. Squires, 2009 .

Discovery of a novel Raf kinase inhibitor.

G. Bollag, J. Lyons, S. Wilhelm, 2001, Endocrine-related cancer.

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

S. Halford, G. Acton, A. Boddy, 2014, Clinical Cancer Research.

Raf pathway inhibitors in oncology.

G. Bollag, J. Lyons, L. Post, 2003, Current opinion in investigational drugs.

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors

J. Doroshow, A. Chen, G. Shapiro, 2020, Cancer Chemotherapy and Pharmacology.

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

J. Doroshow, A. Chen, E. Polley, 2015, Investigational New Drugs.

First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors

G. Shapiro, E. Kwak, J. Lyons, 2014, Clinical Cancer Research.

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer

L. Fazal, M. Reule, J. Lyons, 2012, Cancer science.

Functional Wild‐Type and Carboxy‐Terminal‐Tagged Rat Substance P Receptors Expressed in Baculovirus‐Infected Insect Sf9 Cells

J. Lyons, M. Innis, J. Krause, 1995, Journal of neurochemistry.

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

K. Gelmon, L. Seymour, J. Lyons, 2013, Investigational New Drugs.

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

A. Green, M. Dawson, M. Scott, 2010, British journal of haematology.

Cancer Therapy : Preclinical AT 13148 Is a Novel , Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012 .

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.

Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation

C. Haslett, J. Lyons, L. P. de Sousa, 2011, PloS one.

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177

L. Seymour, H. Hirte, L. Siu, 2014, British Journal of Cancer.

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

S. Kimura, M. Reule, J. Lyons, 2010, Blood.

C3 Toxin Activates the Stress Signaling Pathways, JNK and p38, but Antagonizes the Activation of AP-1 in Rat-1 Cells*

S. Cook, J. Lyons, J. R. Erickson, 1999, The Journal of Biological Chemistry.

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

R. Plummer, I. Judson, T. Yap, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

L. Seymour, J. Lyons, S. Gibson, 2017, Leukemia & lymphoma.

Dominant negative mutants of mitogen-activated protein kinase pathway.

M. J. Arboleda, J. Lyons, B. Hibner, 2001, Methods in enzymology.

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Clinical lymphoma, myeloma & leukemia.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

L. Seymour, T. Reiman, D. Reece, 2016, Leukemia & lymphoma.

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.

T. Holyoake, J. Lyons, P. Gallipoli, 2012, Blood cells, molecules & diseases.

A phase I dose escalation study of AT 9283 , a small molecule inhibitor of aurora kinases , in patients with advanced solid malignancies

R. Plummer, I. Judson, T. Yap, 2012 .

Aurora B kinase inhibition in mitosis: Strategies for optimizing the use of Aurora kinase inhibitors such as AT9283

L. Fazal, M. Reule, J. Lyons, 2009, Cell cycle.

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

L. Seymour, J. Lyons, J. Kuruvilla, 2014 .

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

P. Richardson, P. Hari, J. Lyons, 2013 .

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

S. Plymate, P. Workman, J. Lyons, 2016, Cancer research.

Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.

B. Karlan, F. Kabbinavar, D. Slamon, 2003, Cancer research.

ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth

G. Chessari, J. Lyons, N. Thompson, 2018, Molecular Cancer Therapeutics.

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling

J. Lyons, C. Annunziata, M. Fergusson, 2023, Cancers.

Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

H. Saini, J. Lyons, N. Thompson, 2016, British Journal of Cancer.

G. Bollag, J. Lyons, S. Wilhelm, 2001 .

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

C. Murray, V. Berdini, D. Newell, 2011, Molecular Cancer Therapeutics.

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

C. Murray, V. Berdini, J. Lyons, 2021, Molecular Cancer Therapeutics.

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

J. Lyons, N. Thompson, 2005, Current opinion in pharmacology.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2.

C. Murray, V. Berdini, J. Castro, 2018, Journal of medicinal chemistry.

First-inHuman Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP 90 Inhibitor , AT 13387 , in Patients with Advanced Solid Tumors

G. Shapiro, E. Kwak, J. Lyons, 2014 .

First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors.

G. Shapiro, V. Lock, J. Lyons, 2012 .

The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

J. Fletcher, J. Lyons, N. Thompson, 2012, Molecular Cancer Therapeutics.

Preclinical Development The HSP 90 Inhibitor , AT 13387 , Is Effective against Imatinib-Sensitive and-Resistant Gastrointestinal Stromal Tumor Models

J. Fletcher, J. Lyons, N. Thompson, 2012 .

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

G. Demetri, R. Riedel, M. Heinrich, 2016, European journal of cancer.

Activity of AT13387, a novel, non-ansamycin inhibitor of heat shock protein 90, against gastrointestinal stromal tumors (GIST).

G. Shapiro, J. Lyons, D. Mahadevan, 2013 .

Abstract 2433:In vitroandin vivoantitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.

P. Workman, J. Lyons, S. Eccles, 2013 .

Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.

C. Murray, L. Fazal, J. Lyons, 2007 .

Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma

H. Saini, J. Lyons, R. Ferraldeschi, 2021, Blood advances.

147 POSTER AT13387, a fragment derived clinical candidate is active in lung and melanoma models

L. Fazal, M. Reule, J. Lyons, 2008 .

Dose-escalation study of a second-generation non-ansamycin HSP 90 inhibitor , onalespib ( AT 13387 ) , in combination with imatinib in patients with metastatic gastrointestinal stromal tumour *

G. Demetri, R. Riedel, M. Heinrich, 2022 .

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

W. Qi, V. Lock, J. Lyons, 2007 .

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

S. Halford, G. Acton, A. Boddy, 2014, Clinical Cancer Research.

AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012, Clinical Cancer Research.